Lung cancer is the leading cause of cancer-related deaths in the world. While novel targeted therapeutics are making their way into the clinic, chemotherapeutics remain a mainstay of lung cancer therapies. Delivering chemotherapeutics through inhalation shows promise as a new delivery method with which to treat cancer. The goal of this work was to develop an alternative technology to enhance the delivery of CPT to the lungs through inhalation and overcome the difficulties associated with CPT delivery via other routes, thereby treating lung cancer directly at its location within the body.
Development of inhalable dry-powder formulations for low water-soluble products using spray-dried engineered particles
Inhalation of camptothecin (CPT) may help overcome difficulties with delivery via other routes and treat lung cancer at its location.